ESC 2022: ADVENT-HF: Adaptive Servo Ventilation in Patients with Heart Failure and Sleep Apnea

Подробнее о видео

Watch on Radcliffe Cardiology:

In this short interview filmed onsite at ESC Congress 2022, Dr Douglas Bradley (University of Toronto, Toronto, CA) discusses the findings of the ADVENT-HF Trial (NCT01128816).

ADVENT-HF was designed to determine if a respiratory device, Adaptive Servo Ventilation can reduce the risk of cardiovascular hospitalisations and death in patients with heart failure and sleep apnea. 732 patients were enrolled in the trial, and were randomized to receive either standard HF therapy, or Adaptive Servo Ventilation in addition.

Questions:
-What is the existing evidence to suggest that treating sleep apnea in patients with HF could reduce cardiovascular risk?
-What was the device studied in this trial?
-What was the study design and patient population?
-What were the key findings?
-How can these results impact both patients and practice?
-What further research in this field is needed? Where are the knowledge gaps?

Recorded on-site at ESC Congress 2022, Barcelona.

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.